[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:neuroendocrine-carcinoma:dll3-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Neuroendocrine Carcinoma","DLL3 Gene",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07278479","Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:16:16.169331Z","2026-05-05T02:43:28.190947Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05652686","A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)",[12],"2026-08-26T02:16:14.341106Z","2026-07-19T19:36:05.121911Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT04429087","A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3",[26],"Phase 1","2026-08-03T00:53:42.755927Z","2026-07-05T05:32:16.773103Z"]